Pharma dealmaking for drugs invented in China is putting pressure on U.S. biotechs to compete harder, according to investors ...

Announcement of the 15 medicines chosen for the second round of negotiations is one of the Biden administration’s final ...

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the ...

Intra-Cellular has had success selling Caplyta, a brain-rebalancing drug that's approved to treat schizophrenia and bipolar ...

While Biogen has made an opportunistic bid for partner Sage, its top executive seemed to play down the urgency for his ...

Roche's core research spans five large areas. Boris Zaïtra, who now leads corporate business development, is confident his ...

Drug executives talked M&A and the incoming administration, but also weighed the outlook for cell and gene therapy developers ...

A high-dose form of Novo’s obesity drug led to 20% weight loss over 72 weeks. Meanwhile, Atara got a complete response letter ...

Agency commissioners voted unanimously on Tuesday to publish the report, which makes a similar attack on the drug middlemen ...

The review, which was spurred by controversy over the FDA's Aduhelm approval, recommends two main changes in agency ...

Analysts say the deal, which would give Biogen full control over the drug Zurzuvae, could be a smart financial move. Yet it's ...

Regenxbio, a prolific developer of gene therapy technology, will hand Japan’s Nippon Shinyaku certain rights to two ...